Towards a Functional Cure for HBV - The COMMIT Cohort Study

Hepatitis B virus (HBV) infection can be treated, but therapy is usually lifelong and has side effects, so a cure for HBV is a critical endpoint. This study examines the key steps to HBV cure in the setting of HIV-HBV co-infection, where rates of development of antibodies against HBV after starting HBV treatment are higher than in people with HBV alone starting treatment. In Asia both HBV and HIV are common so this provides a unique opportunity to study HBV. We will investigate how an effective immune response against the two main HBV proteins is developed. If we can understand how the immune response works against HBV, this could be used to develop new therapies towards a cure for HBV

NCT Number	NCT03645044
Lead Sponsor	University of Melbourne Collaborators: National Health and Medical Research Council, Australia, The University of Western Australia, University of Adelaide, The HIV Netherlands Australia Thailand Research Collaboration, University of Malaya, YR Gaitonde Centre for AIDS Research and Education, Melbourne Health
Conditions	Hiv, HBV Coinfection
Enrollment	102 participants
Start Date	2018-05-24
Primary Completion	2022-04-29 (estimated)
Study Completion	2025-07 (estimated)
Updated on ClinicalTrials.gov	2025-07-17